Как повысить приверженность к лечению у больных артериальной гипертонией и дислипидемией?
https://doi.org/10.18705/1607-419X-2009-15-3-359-365
Аннотация
Статья посвящена проблеме лечения больных артериальной гипертонией и дислипидемией. Обсуждаются вопросы приверженности к лечению антигипертензивными и гиполипидемическими средствами. Рассматриваются эффекты первой фиксированной комбинации CADUET (амлодипин/аторвастатин), которая действует более чем на один фактор риска.
Об авторе
Ю. М. Лопатин
Волгоградский государственный медицинский университет, Волгоградский областной кардиологический центр
Россия
Россия
Список литературы
1. Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25. - P. 1105-1187.
2.
3. European society of hypertension - European society of cardiology guidelines for the management of arterial hypertension // J.Hypertens. - 2003. - Vol. 21. - P. 1011-1053.
4.
5. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study // Am. J. Hypertens. - 2000. - Vol. 13 (1 Pt 2). - P. 3S-10S.
6.
7. Шальнова С.А., Деев А.Д., Оганов Р.Г. Распространенность основных факторов риска среди мужчин и женщин Российской Федерации старше 30 лет // Кардиоваск. Тер. Профилакт. - 2005. - № 1. - С. 4-9.
8.
9. National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) // JAMA. - 2001. - Vol. 285. - P. 2486-2497.
10.
11. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease: overall findings and differences by age for 316,099 white men. Multiple risk factor intervention trial research group // Arch. Intern. Med. - 1992. - Vol. 152. - P. 56-64.
12.
13. Lowe L.P., Greenland P., Ruth K.J. et al. Impact of major cardiovascular risk factors, particularly in combination, on 22-year mortality in women and men // Arch. Intern. Med. - 1998. - Vol. 158. - Vol. 2007-2014.
14.
15. Thomas F., Beah K., Guize L. et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women // Eur. Heart J. - 2002. - Vol. 23. - P. 528-535.
16.
17. Veronesi M., Borghi C., Immordino V. et al. Blood pressure reactivity and development of stable hypertension in borderline hypertensives. Role of plasma cholesterol [Abstract] // Am. J. Hypertens. - 1998. - Vol. 11. - P. 218A.
18.
19. Sposito A.C. Emerging insights into hypertension and dyslipidaemia synergies // Eur. Heart J. - 2004. - Vol. 6 (suppl. G). - P. G8-G12.
20.
21. Borghi C., Prandin M.G., Costa F.V. et al. Use of statins and blood pressure control in hypertensive patients with hypercholesterolemia // J. Cardiovasc. Pharmacol. - 2000. - Vol. 35. - P. 549-555.
22.
23. Calvo С., Hermida R.C., Ayala D.E. et al. Effects of atorvastatin on ambulatory blood pressure in hyperlipidemic patients with untreated mild hypertension // Am. J. Hypertens. - 2003. - Vol. 16 (5, Part 2). - P. 44A.
24.
25. Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial // Lancet. - 2003. - Vol. 361. - P. 1149-1158.
26.
27. Sever P.S., Poulter N.R., Dahlof B. et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lopid-Lowering Arm (ASCOT-LLA) // Am. J. Cardiol. - 2005. - Vol. 96 (5 suppl.). - P. 39-44F.
28.
29. Dahlof B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial // Lancet. - 2005. - Vol. 366. - P. 895-906.
30.
31. Sever P.S., Dahlof B., Poulter N.P. et al. for the ASCOT Investigators. Anglo-Scandinavian cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA) revisited: Interaction of antihypertensive and lipid lowering therapy // Circulation. - 2005. - Vol. 112 (suppl.). - P. II-134.
32.
33. MacDonald T.M., Morant S.V., baker C.L. et al. Treatment patterns for hypertension, dyslipidemia, and both conditions in the United Kingdom: 1997 to 2001. Abstract of 20th scientific meeting of the International society of hypertension. Sao Paolo, Brazil, February 15-19, 2004.
34.
35. Chapman R.H., Benner J.S., Petrilla A.A. et al. Adherence with concomitant antihypertensive and lipid-lowering therapy. Abstracts of 9th annual International meeting of the International society for pharmacoeconomics and outcomes research. Arlington, USA, May 16-19, 2004.
36.
37. Schwartz J.S., McLaughlin T., Griffis D. et al. Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both. Abstracts of 52th annual scientific session of American college of cardiology, Chicago, USA, March 30-April 2, 2003.
38.
39. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension // Manag. Care. - 2000. - Vol. 9 (9 suppl.). - P. 2-6.
40.
41. Flack J.M., Houston M., Neutel J. et al. Efficacy and safety of atorvastatin plus amlodipine versus either agent alone in patients with concomitant dyslipidemia and hypertension: the AVALON study // J. Hypertens. - 2004. - Vol. 22 (suppl. 1). - P. 125.
42.
43. Preston R.A., Harvey P., Herfert O. et al. The efficacy and safety of fixed-dose combinations of amlodipine and atorvastatin in the treatment of patients with concomitant hypertension and dyslipidemia // Am. J. Hypertens. - 2004. - Vol. 17(5 Pt 2). - P. 185A.
44.
45. Preston R.A., Harvey P., Herfert O. et al. Reduction of Framingham cardiovascular risk with concomitant treatment of hypertension/dyslipidemia with amlodipine/atorvastatin // Am. J. Hypertens. - 2005. - Vol. 18 (5 suppl.1). - P. A226.
46.
47. Preston R.A., Sun F., Tarasenko L. Safety and tolerability of coadministrered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the Respond study // Am. J. Hypertens. - 2005. - Vol. 18 (5 suppl.1). - P. A92-A93.
48.
49. Blank R., LaSalle J., Reeves R. Et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (The Amlodipine/Atorvastatin Gemini Study) // J. Clin. Hypertens. - 2005. - Vol. 7. - P. 264-273.
50.
Рецензия
Для цитирования:
Лопатин Ю.М. Как повысить приверженность к лечению у больных артериальной гипертонией и дислипидемией? Артериальная гипертензия. 2009;15(3):359-365. https://doi.org/10.18705/1607-419X-2009-15-3-359-365
For citation:
Lopatin Y. How to increase patients' compliance in hypertension and dyslipidemia? "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(3):359-365. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-3-359-365
Просмотров: 620
Послать статью по эл. почте 